WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that its Founder and Chief Executive Officer, Wes Kaupinen, will take part in a fireside chat at the Jones Healthcare and Technology Innovation Conference. The discussion is scheduled for Wednesday, April 9, 2025, at 2:00 p.m. PT.
The live event will be streamed via webcast, with an archived replay available for approximately 90 days afterward on Palvella’s Events and Presentations page.
Palvella, a clinical-stage biopharmaceutical company, is known for its focus on developing treatments for rare genetic skin diseases that currently lack FDA-approved therapies. Its work is centered around the QTORIN™ platform, a proprietary technology designed to address these underserved conditions.
The company’s lead investigational product, QTORIN™ rapamycin 3.9% anhydrous gel, is being tested in two clinical trials. The Phase 3 SELVA trial investigates its use in microcystic lymphatic malformations, while the Phase 2 TOIVA trial evaluates potential treatment for cutaneous venous malformations.
While QTORIN™ rapamycin remains under investigation and is not yet FDA-approved, its development underscores Palvella’s commitment to addressing the unmet needs of patients with rare genetic skin diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.